Tag Archives: Swayampakula Ramakanth

H.C. Wainwright Maintains a Buy Rating on Ziopharm Oncology (ZIOP)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Ziopharm Oncology (ZIOP – Research Report), with a price target of $6.50. The company’s shares closed last Monday at $4.11. According to TipRanks.com, Ramakanth is

H.C. Wainwright Maintains a Buy Rating on AVEO Pharma (AVEO)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AVEO Pharma (AVEO – Research Report), with a price target of $1.75. The company’s shares closed last Monday at $0.84, close to its 52-week low

Why Did H.C. Wainwright Downgrade Tocagen Inc’s Stock?

H.C. Wainwright analyst Swayampakula Ramakanth downgraded Tocagen Inc (TOCA – Research Report) to Hold today. The company’s shares closed last Monday at $0.90, close to its 52-week low of $0.73. Ramakanth noted: “We lower our rating of TOCA to and

Inmune Bio Inc (INMB) Receives a Buy from H.C. Wainwright

In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Inmune Bio Inc (INMB – Research Report), with a price target of $11.50. The company’s shares closed last Monday at $6.14. Ramakanth observed: “We maintain

Analyst Explains Why They Upgraded Their Rating on AVEO Pharma (AVEO)

H.C. Wainwright analyst Swayampakula Ramakanth upgraded AVEO Pharma (AVEO – Research Report) to Buy today and set a price target of $1.75. The company’s shares closed last Monday at $0.92, close to its 52-week low of $0.49. Ramakanth said: “We

Analysts Offer Insights on Healthcare Companies: Inmune Bio Inc (NASDAQ: INMB) and Vaxart Inc (NASDAQ: VXRT)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inmune Bio Inc (INMB – Research Report) and Vaxart Inc (VXRT – Research Report) with bullish sentiments. Inmune Bio Inc (INMB) H.C.